Use of PD-1 and PD-L1 Inhibitors after First-Line Therapy in Esophageal Cancer Patients in the US
| Autor: | Gisoo Barnes, Heather L Handl, Jason C. Allaire, Mark Balk, Soraya Azmi, Keri Yang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms Esophageal Neoplasms medicine.medical_treatment Programmed Cell Death 1 Receptor 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine First line therapy PD-L1 Internal medicine Claims data medicine Humans 030212 general & internal medicine Immune Checkpoint Inhibitors Chemotherapy biology business.industry General Medicine Esophageal cancer medicine.disease First line treatment Nivolumab biology.protein Female business |
| DOI: | 10.6084/m9.figshare.14599853.v1 |
| Popis: | Esophageal cancer (EC) makes up 3.2% of all cancers but ranks sixth among cancer-related deaths worldwide. This real-world analysis determined the use of PD-1/PD-L1 (PD[L]1) inhibitors in EC patients after receiving first-line therapy.Newly diagnosed EC patients initiating first-line treatment were identified in the IBM MarketScan administrative claims databases during the study period (1 May 2015 to 31 October 2020) using ICD-9/ICD-10 codes. Patients were assigned to either the chemotherapy only, radiation only, chemotherapy plus radiation (chemoradiation), or esophageal transhiatal/transthoracic surgery cohorts.7276 EC patients started first-line therapy (chemotherapy only = 2502, radiation only = 3355, chemoradiation = 1180, surgery = 239). The average age at diagnosis was 62 years and 23% were female. The median time from start of first-line therapy to utilization of a PD(L)1 inhibitor was 259 days. Pembrolizumab (72%) was the most frequently used PD(L)1 inhibitor across the three cohorts, followed by nivolumab (25%). Furthermore, the number of patients receiving a PD(L)1 inhibitor increased each year with the majority (73%) of use occurring between 2018 and 2020.Findings from this real-world study suggest that PD(L)1 inhibitors are increasingly used after first-line therapies in EC, especially among patients initially receiving chemotherapy only. New immunological therapies such as PD(L)1 inhibitors hold great promise for patients with solid tumors. A clearer understanding of their real-world utilization is critical. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|